X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs SUN PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. SUN PHARMA WOCKHARDT LTD./
SUN PHARMA
 
P/E (TTM) x -19.0 41.9 - View Chart
P/BV x 2.0 3.3 62.1% View Chart
Dividend Yield % 0.0 0.4 0.5%  

Financials

 WOCKHARDT LTD.   SUN PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
SUN PHARMA
Mar-18
WOCKHARDT LTD./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,012701 144.5%   
Low Rs532433 122.7%   
Sales per share (Unadj.) Rs355.9110.4 322.3%  
Earnings per share (Unadj.) Rs-60.311.0 -549.1%  
Cash flow per share (Unadj.) Rs-46.817.2 -271.4%  
Dividends per share (Unadj.) Rs0.012.00 0.5%  
Dividend yield (eoy) %00.4 0.4%  
Book value per share (Unadj.) Rs257.8158.8 162.3%  
Shares outstanding (eoy) m110.632,399.26 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.25.1 42.2%   
Avg P/E ratio x-12.851.6 -24.8%  
P/CF ratio (eoy) x-16.532.9 -50.2%  
Price / Book Value ratio x3.03.6 83.9%  
Dividend payout %018.2 -0.1%   
Avg Mkt Cap Rs m85,3791,360,021 6.3%   
No. of employees `0006.317.8 35.2%   
Total wages/salary Rs m9,37153,671 17.5%   
Avg. sales/employee Rs Th6,295.014,890.9 42.3%   
Avg. wages/employee Rs Th1,498.33,017.1 49.7%   
Avg. net profit/employee Rs Th-1,066.31,480.6 -72.0%   
INCOME DATA
Net Sales Rs m39,369264,895 14.9%  
Other income Rs m1,2028,388 14.3%   
Total revenues Rs m40,571273,282 14.8%   
Gross profit Rs m1856,081 0.0%  
Depreciation Rs m1,49514,998 10.0%   
Interest Rs m2,5555,176 49.4%   
Profit before tax Rs m-2,83044,295 -6.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582-9,505 37.7%   
Tax Rs m2578,452 3.0%   
Profit after tax Rs m-6,66926,338 -25.3%  
Gross profit margin %021.2 0.2%  
Effective tax rate %-9.119.1 -47.6%   
Net profit margin %-16.99.9 -170.4%  
BALANCE SHEET DATA
Current assets Rs m33,796316,359 10.7%   
Current liabilities Rs m26,917198,643 13.6%   
Net working cap to sales %17.544.4 39.3%  
Current ratio x1.31.6 78.8%  
Inventory Days Days7995 83.7%  
Debtors Days Days89108 82.9%  
Net fixed assets Rs m39,664213,178 18.6%   
Share capital Rs m5532,399 23.1%   
"Free" reserves Rs m27,968378,606 7.4%   
Net worth Rs m28,522381,006 7.5%   
Long term debt Rs m21,73117,721 122.6%   
Total assets Rs m81,620643,028 12.7%  
Interest coverage x-0.19.6 -1.1%   
Debt to equity ratio x0.80 1,638.2%  
Sales to assets ratio x0.50.4 117.1%   
Return on assets %-5.04.9 -102.8%  
Return on equity %-23.46.9 -338.2%  
Return on capital %-7.710.0 -76.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80740,816 24.0%   
Fx outflow Rs m1,78930,143 5.9%   
Net fx Rs m8,01910,673 75.1%   
CASH FLOW
From Operations Rs m68439,072 1.8%  
From Investments Rs m6,302-33,708 -18.7%  
From Financial Activity Rs m-7,695-15,393 50.0%  
Net Cashflow Rs m-664-7,359 9.0%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 5.1 44.8%  
FIIs % 7.7 23.0 33.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   67,757 133,026 50.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  MERCK LTD  NOVARTIS  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Nov 15, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS